Delirium

Created: June 28, 2021

Last Updated: November 18, 2023

Contributor(s):

ERAS Cardiac Collaborative Network

Editor(s):

Cheryl Crisafi MSN RN CNL

Amanda Rea DNP CRNP AGACNP-BC CCRN CMC CSC E-AEC

Gina McConnell RN BSN CCRN

Shannon Crotwell RN BSN CCRN

Alexander Gregory MD FRCPC

Summary

Post-operative cognitive dysfunction, including delirium, can have significant impact on a patient’s recovery and long-term quality of life following cardiac surgery. Pre-operative risk stratification, early detection, and management of delirium after cardiac surgery are essential. A multidisciplinary approach involving physicians, nurses, pharmacists, and other healthcare professionals will help ensure optimal patient care.

Post-operative Cognitive Dysfunction (POCD), including delirium, occurs more commonly following cardiac surgery than many healthcare providers recognize. The effects on patient outcomes include:

  • Increased morbidity & mortality
  • Increased ICU & hospital length of stay
  • Long-term cognitive decline
  • Increased healthcare costs
  • Impaired mental health
  • Functional decline and poorer quality of life
  • Caregiver burden
  • Need for discharge to a rehabilitation facility

Several risk factors have been identified that can increase the likelihood of developing POCD. These include:

  • Advanced age
  • Pre-existing cognitive impairment
  • Comorbidities- ex: diabetes, cerebrovascular disease, smoking, alcohol misuse, etc.
  • Duration of cardiopulmonary bypass
  • Hemodynamic instability
  • Infection
  • Pain
  • Medications
  • Malnutrition
  • Frailty


Screening for delirium in critically ill patients involves a series of standardized assessments and evaluations to identify the presence of acute confusion, altered mental status, and other cognitive impairments. Several tools and methods may be employed in clinical settings to diagnose and manage delirium efficiently.

Management and prevention strategies for postoperative delirium include:

  • Pre-operative risk stratification
  • Medication review
  • Environmental modifications- ex: keeping the patient’s environment quiet, well-lit, and familiar to reduce confusion.
  • Physical and cognitive activity
  • Family involvement
  • Optimal treatment of co-existing medical conditions
  • Pharmacologic treatment options

_____________________________________________________________________________________________________________________________


This summary was written with assistance from artificial intelligence. All text was reviewed, edited, and supplemented by the listed editor(s). Reference: OpenAI. (2023). ChatGPT (Sept 25 version) [Large language model]. https://chat.openai.com/chat

ERAS Cardiac VTC Disclaimer:

The VTC, and all included content, is intended to inform ERAS Cardiac Members in a multitude of topics related to enhanced recovery. The information included has been provided by other enhanced recovery experts and should be used for educational purposes only. It is not intended to describe, recommend, or suggest any specific medical practice or intervention, nor should it be considered as formal medical advice or consultation. The ERAS Cardiac Society cannot guarantee that the information on the VTC is accurate or complete in every respect. Therefore, ERAS Cardiac Society is not responsible for any errors or omissions in the content, or medical results that occur with the application of the information obtained while using the VTC. All healthcare professionals should continue to use sound clinical judgment and prescribe therapies based on the best medical knowledge at their disposal.

All the material presented on the VTC is the intellectual property of the ERAS Cardiac Society, its contributors, and its sponsors. Unless explicitly stated, the information, images, audio, video, and other content may not be reproduced (in whole or in part) in any way without the written permission of the ERAS Cardiac Society.

If you have any questions or comments about the ERAS Cardiac VTC, please email: VTC@erascardiac.org

Educational Materials

Post-Operative Cognitive Dysfunction after Cardiac Surgery
This video is a recorded session from the ERAS Cardiac Virtual Meeting in 2021. Speakers and discussants include members of our international network of ERAS experts in conjunction with TopMed Talks. In this session, participants discuss the impact of post-operative cognitive dysfunction following cardiac surgery, including delirium. Other topics include options for screening and treatment.

References:

  1. Arora RC, Djaiani G, Rudolph JL. Detection, Prevention, and Management of Delirium in the Critically Ill Cardiac Patient and Patients Who Undergo Cardiac Procedures. Can J Cardiol. 2017;33(1):80-87.
  2. Nguyen Q, Uminski K, Hiebert BM, Tangri N, Arora RC. Midterm outcomes after postoperative delirium on cognition and mood in patients after cardiac surgery. J Thorac Cardiovasc Surg. 2018;155(2):660-667.e2.
  3. Dubiel C, Hiebert BM, Stammers AN, et al. Delirium definition influences prediction of functional survival in patients one-year postcardiac surgery. J Thorac Cardiovasc Surg. Published online July 16, 2020:1-12
  4. Rudolph JL, Jones RN, Levkoff SE, et al. Derivation and validation of a preoperative prediction rule for delirium after cardiac surgery. Circulation. 2009;119(2):229-236.
  5. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Vol 46.; 2018.
  6. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001;29(7):1370-1379. http://www.ncbi.nlm.nih.gov/pu...
  7. Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med. 2001;27(5):859-864.
  8. Neufeld KJ, Leoutsakos JS, Sieber FE, et al. Evaluation of two delirium screening tools for detecting post-operative delirium in the elderly. Br J Anaesth. 2013;111(4):612-618.
  9. Hov KR, Neerland BE, Undseth Ø, et al. The Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID: a randomised placebo-controlled trial. International Journal of Geriatric Psychiatry. 2019;34(7):974-981.
  10. Girard TD, Exline MC, Carson SS, et al. Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness. New England Journal of Medicine. Published online 2018:NEJMoa1808217.
  11. Page VJ, Ely EW, Gates S, et al. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. 2013;1(7):515-523.
  12. White DB, Angus DC, Shields AM, et al. A Randomized Trial of a Family-Support Intervention in Intensive Care Units. New England Journal of Medicine. 2018;378(25):2365-2375.
Next